BioMarin Pharmaceutical | Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
Agios Pharmaceuticals USD 89.13M 3.58M 2025-12
Alnylam Pharmaceuticals USD 1.66B 167M 2025-12
Amgen USD 9.13B 316M 2025-12
Bayer EUR 5.9B 1.34B 2025-09
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Gilead Sciences USD 7.33B 2.19B 2025-09
Incyte USD 3.58B 650.78M 2025-12
Insmed USD 510.44M 175.68M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
Moderna USD 2.6B 1.46B 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
PTC Therapeutics USD 984.65M 312.03M 2025-12
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Ultragenyx Pharmaceutical USD 202.51M 36.4M 2025-09
United Therapeutics USD 1.56B 217M 2025-12
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12


BioMarin Pharmaceutical Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2026.